IP83-23: EVALUATING THE SURROGACY OF INTERMEDIATE CLINICAL ENDPOINTS FOR OVERALL SURVIVAL IN PATIENTS WHO RECEIVED RADICAL CYSTECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOTHERAPY FOR LOCALIZED MUSCLE INVASIVE BLADDER CANCER: A REAL-WORLD COHORT STUDY